Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.
$455.17 0.53 (0.12)%
Market Cap 47.51B
05/26/17 4:00 PM ET | Minimum 20 minutes delay.
Stock information provided by eSignal.
Regeneron Announces ANGPTL3/Evinacumab Publication in New England Journal of Medicine and Positive Phase 2 Data in People with HoFHRead on
Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult PatientsRead on
Bernstein 33rd Annual Strategic Decisions Conference
May 31, 2017 | 5:00 PM ET
2017 Annual Meeting of Shareholders
Jun 9, 2017 | 10:30 AM ET